Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
暂无分享,去创建一个
R. Elashoff | R. Elashoff | M. Roth | M. Mayes | J. Golden | Ning Li | J. Goldin | C. Strange | C. Read | D. Furst | R. Simms | J. Varga | D. Khanna | R. Wise | V. Steen | P. Clements | J. Seibold | B. Fessler | V. Hsu | R. Silver | M. Olman | A. Theodore | M. Bolster | D. Tashkin | B. White | M. Metersky | Gang Li | F. Wigley | N. Rothfield | D. Schraufnagel | K. Mubarak | D. J. Riley | Michael D. Roth | E. Parsley | M. K. Connolly | E. Arriola | D. Riley | M. Connolly | Robert W. Simms | David J. Riley | Dean E. Schraufnagel | M. Kari Connolly | Charlie Strange | John Varga | Jeffrey A. Golden | Daniel E. Furst | James R. Seibold | M. Mayes | Naomi F. Rothfield | D. P. Tashkin | Philip J. Clements | Dinesh Khanna | Richard M. Silver | Barbara White | Jonathan G. Goldin | Arthur C. Theodore | Robert A. Wise | Fredrick M. Wigley | Virginia D. Steen | Charles Read | Ed Parsley | Kamal Mubarak | M. Connolly | Mitchell A. Olman | Ning Li | D. Tashkin | Charles A Read | Maureen D Mayes | F. Wigley | Jonathan Goldin
[1] Gang Li,et al. A Bayesian approach to joint analysis of longitudinal measurements and competing risks failure time data , 2007, Statistics in medicine.
[2] K. Lewis. Cyclophosphamide versus Placebo in Scleroderma Lung Disease , 2008 .
[3] P. Mielke,et al. Permutation Methods: A Distance Function Approach , 2007 .
[4] R. Elashoff,et al. An approach to joint analysis of longitudinal measurements and competing risks failure time data , 2007, Statistics in medicine.
[5] P. Emery,et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.
[6] F. Martinez,et al. Cyclophosphamide for scleroderma lung disease. , 2006, The New England journal of medicine.
[7] Charlie Strange,et al. Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.
[8] D. Mahler,et al. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. , 2006, Proceedings of the American Thoracic Society.
[9] Arl Medford,et al. British Thoracic Society , 2004 .
[10] Shin Ta Liu,et al. Permutation Methods: A Distance Function Approach , 2002, Technometrics.
[11] J. Ioannidis,et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. , 2002, The Journal of rheumatology.
[12] W. Busse,et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.
[13] M. Mayes,et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. , 2001, Arthritis and rheumatism.
[14] R. Wise,et al. Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis , 2000, Annals of Internal Medicine.
[15] S. Spencer,et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.
[16] David E. Booth,et al. Analysis of Incomplete Multivariate Data , 2000, Technometrics.
[17] S. Jimenez,et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. , 1998, The Journal of rheumatology.
[18] Kenneth J. Berry,et al. Permutation Covariate Analyses of Residuals Based on Euclidean Distance , 1997 .
[19] T. Medsger,et al. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. , 1997, Arthritis and rheumatism.
[20] C. Vogelmeier,et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. , 1996, American journal of respiratory and critical care medicine.
[21] Guy Hoffman,et al. Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis , 1996, Annals of Internal Medicine.
[22] John L. Hankinson,et al. Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.
[23] C. Kwoh,et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. , 1995, Arthritis and rheumatism.
[24] Richard W. Martin,et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. , 1995, The Journal of rheumatology.
[25] J. Hankinson,et al. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update. , 1995, American journal of respiratory and critical care medicine.
[26] T. Medsger,et al. Severe restrictive lung disease in systemic sclerosis. , 1994, Arthritis and rheumatism.
[27] T. Medsger,et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. , 1994, Arthritis and rheumatism.
[28] A. Lundin,et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. , 1994, Arthritis and rheumatism.
[29] Physiologists. Guidelines for the measurement of respiratory function , 1994 .
[30] R. Silver,et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. , 1993, The Journal of rheumatology.
[31] A. Bühlmann. [Pathophysiology of dyspnea]. , 1989, Schweizerische medizinische Wochenschrift.
[32] C. Wells,et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.
[33] J. Vandenbroucke,et al. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. , 1983, Annals of the rheumatic diseases.
[34] R M Gardner,et al. Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.
[35] A H Morris,et al. Standardized single breath normal values for carbon monoxide diffusing capacity. , 2015, The American review of respiratory disease.
[36] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[37] James F. Fries,et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.
[38] P. J. Huber. Robust Regression: Asymptotics, Conjectures and Monte Carlo , 1973 .